Skip to main content

Table 1 Baseline characteristics of the entire cohort (N = 149)

From: Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience

Characteristics

No. (%)

Age, median (range), years

68 (45–86)

PSA at mCRPC

 

 ≤ 20 ng/mL

80 (53.7)

 > 20 ng/mL

69 (46.3)

Gleason scorea

 

 ≤ 8

70 (47.0)

 9–10

79 (53.0)

ECOG

 

 0–1

105 (70.5)

 > 1

44 (29.5)

Prognostic indexb

 

 Good

65 (43.6)

 Intermediate

75 (50.3)

 Poor

9 (6.0)

Synchronous metastasis

127 (85.2)

Oligometastasis

58 (38.9)

Chemo-naïve

123 (82.6)

  1. PSA prostate-specific antigen, mCRPC metastatic castration-resistant prostate cancer, Chemo-naïve chemotherapy-naïve upon abiraterone treatment
  2. aGleason score at diagnosis of prostate cancer
  3. bThe COU-AA-301 prognostic index